P2RX7 and neoplasm: Given that many cancer cells express high levels of P2X7 receptors (notably mutated, truncated, or splice variants that are not able to trigger P2X7-dependent cell death), and that its tonic activation in the tumor microenvironment is associated with tumor proliferation and invasiveness, P2X7-blockade was envisioned as a possible cancer therapy.